Krystal Biotech, Inc. (KRYS)

NMS – Real vaqt narxi. Valyuta: USD

330.98

+3.94 (1.20%)

Bozor ochiq: Aug 12, 2026, 11:57 AM EDT

325.00

-2.05 (-0.63%)

Oldingi bozordan keyin: Aug 11, 2026, 7:56 PM EDT

04.08.2026

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

KRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.

03.08.2026

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

03.08.2026

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

03.08.2026

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech NASDAQ: KRYS reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overseas.

03.08.2026

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $1.79 per share, beating the Zacks Consensus Estimate of $1.7 per share. This compares to earnings of $1.29 per share a year ago.

03.08.2026

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S.

Videolar

No Data

There is no data to display

Press-relizlar

03.08.2026

Krystal Biotech, Inc. (KRYS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Krystal Biotech, Inc. (KRYS)

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Videolar

No Data

Press-relizlar

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Videolar

No Data

Press-relizlar

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Search stocks

Krystal Biotech, Inc. (KRYS)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Krystal Biotech, Inc. (KRYS)

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Videolar

No Data

Press-relizlar

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus

Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

Krystal Biotech Q2 Earnings Call Highlights

Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results

Videolar

No Data

Press-relizlar

Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results